Cytokinetics (CYTK) is setting up as an interesting event-driven biotech trade into November, with the options market beginning to position around a major FDA decision while the stock sits near the lower end of its recent range.
biotech
Erasca’s November Catalyst: Promising Data, High Expectations and Strategic Optionality
The company’s lead drug, ERAS-0015, has shown encouraging early results. On November 20, Erasca will provide updated clinical data that could produce a large move in the stock.